Clinical Trial Update: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating camrelizumab with or without apatinib plus SOX chemotherapy for gastric or gastroesophageal junction adenocarcinoma; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Ruijin Hospital | Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING